参考文献:

［1］ZHOU J, ZHOU F, WANG W, et al. Epidemiological feature of NAFLD from 1999 to 2018 in China［J］. Hepatology, 2020, 75(5): 1851-1864.

［2］ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis［J］. Hepatology, 2019, 70(4): 1119-1133.

［3］LONARDO A, NASCIMBENI F, MANTOVANI A, et al. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?［J］. J Hepatol, 2018, 68(2): 335-352.

［4］MILLS KT, STEFANESCU A, HE J. The global epidemiology of hypertension［J］. Nat Rev Nephrol, 2020, 16(4): 223-237.

［5］LPEZ-SUREZ A, GUERRERO JM, ELVIRA-GONZLEZ J, et al. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase［J］. Eur J Gastroenterol Hepatol, 2011, 23(11): 1011-1017.

［6］LORBEER R, BAYERL C, AUWETER S, et al. Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease［J］. J Hypertens, 2017, 35(4): 737-744.

［7］ANENI EC, ONI ET, MARTIN SS, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk［J］. J Hypertens, 2015, 33(6): 1207-1214.

［8］FENG RN, DU SS, WANG C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population［J］. World J Gastroenterol, 2014, 20(47): 17932-17940.

［9］BONNET F, GASTALDELLI A, PIHAN-LE BARS F, et al. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies［J］. J Hypertens, 2017, 35(3): 493-500.

［10］HUH JH, AHN SV, KOH SB, et al. A prospective study of fatty liver index and incident hypertension: The KoGES-ARIRANG study［J］. PLoS One, 2015, 10(11): e0143560.

［11］RYOO JH, SUH YJ, SHIN HC, et al. Clinical association between non-alcoholic fatty liver disease and the development of hypertension［J］. J Gastroenterol Hepatol, 2014, 29(11): 1926-1931.

［12］SUNG KC, WILD SH, BYRNE CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension［J］. J Hepatol, 2014, 60(5): 1040-1045.

［13］QIAN LY, TU JF, DING YH, et al. Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population: Normal is not the new normal［J］. Medicine (Baltimore), 2016, 95(29): e4293.

［14］WANG Y, ZENG Y, LIN C, et al. Hypertension and non-alcoholic fatty liver disease proven by transient elastography［J］. Hepatol Res, 2016, 46(13): 1304-1310.

［15］MA J, HWANG SJ, PEDLEY A, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors［J］. J Hepatol, 2017, 66(2): 390-397.

［16］SORRENTINO P, TERRACCIANO L, D’ANGELO S, et al. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension［J］. Am J Gastroenterol, 2010, 105(2): 336-344.

［17］SINGH S, ALLEN AM, WANG Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies［J］. Clin Gastroenterol Hepatol, 2015, 13(4): 643-654.

［18］European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease［J］. J Hepatol, 2016, 64(6): 1388-1402.

［19］NAKAMURA M, YAMAZAKI O, SHIRAI A, et al. Preserved Na/HCO3 cotransporter sensitivity to insulin may promote hypertension in metabolic syndrome［J］. Kidney Int, 2015, 87(3): 535-542.

［20］ALAM S, MUSTAFA G, ALAM M, et al. Insulin resistance in development and progression of nonalcoholic fatty liver disease［J］. World J Gastrointest Pathophysiol, 2016, 7(2): 211-217.

［21］KHAN RS, BRIL F, CUSI K, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease［J］. Hepatology, 2019, 70(2): 711-724.

［22］BOLLER S, JOBLIN BA, XU L, et al. From signal transduction to signal interpretation: An alternative model for the molecular function of insulin receptor substrates［J］. Arch Physiol Biochem, 2012, 118(3): 148-155.

［23］GUO S. Insulin signaling, resistance, and the metabolic syndrome: Insights from mouse models into disease mechanisms［J］. J Endocrinol, 2014, 220(2): T1-T23.

［24］HORITA S, SEKI G, YAMADA H, et al. Insulin resistance, obesity, hypertension, and renal sodium transport［J］. Int J Hypertens, 2011, 2011: 391762.

［25］ARTUNC F, SCHLEICHER E, WEIGERT C, et al. The impact of insulin resistance on the kidney and vasculature［J］. Nat Rev Nephrol, 2016, 12(12): 721-737.

［26］MINEMURA M, SHIMIZU Y. Gut microbiota and liver diseases［J］. World J Gastroenterol, 2015, 21(6): 1691-1702.

［27］JI Y, YIN Y, LI Z, et al. Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD)［J］. Nutrients, 2019, 11(8): 1712.

［28］MARQUES FZ, MACKAY CR, KAYE DM. Beyond gut feelings: How the gut microbiota regulates blood pressure［J］. Nat Rev Cardiol, 2018, 15(1): 20-32.

［29］LEUNG C, RIVERA L, FURNESS JB, et al. The role of the gut microbiota in NAFLD［J］. Nat Rev Gastroenterol Hepatol, 2016, 13(7): 412-425.

［30］KANG Y, CAI Y. Gut microbiota and hypertension: From pathogenesis to new therapeutic strategies［J］. Clin Res Hepatol Gastroenterol, 2018, 42(2): 110-117.

［31］TE RIET L, van ESCH JH, ROKS AJ, et al. Hypertension: Renin-angiotensin-aldosterone system alterations［J］. Circ Res, 2015, 116(6): 960-975.

［32］PASCHOS P, TZIOMALOS K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment［J］. World J Hepatol, 2012, 4(12): 327-331.

［33］MATTHEW MORRIS E, FLETCHER JA, THYFAULT JP, et al. The role of angiotensin II in nonalcoholic steatohepatitis［J］. Mol Cell Endocrinol, 2013, 378(1-2): 29-40.

［34］WU Y, MA KL, ZHANG Y, et al. Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease［J］. Liver Int, 2016, 36(10): 1525-1534.

［35］TOBLLI JE, MUOZ MC, CAO G, et al. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats［J］. Obesity (Silver Spring), 2008, 16(4): 770-776.

［36］POLYZOS SA, KOUNTOURAS J, MANTZOROS CS, et al. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: A randomized controlled trial［J］. Diabetes Obes Metab, 2017, 19(12): 1805-1809.

［37］YOKOHAMA S, YONEDA M, HANEDA M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis［J］. Hepatology, 2004, 40(5): 1222-1225.

［38］GEORGESCU EF, IONESCU R, NICULESCU M, et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis［J］. World J Gastroenterol, 2009, 15(8): 942-954.

［39］MILIC S, MIKOLASEVIC I, KRZNARIC-ZRNIC I, et al. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options［J］. Drug Des Devel Ther, 2015, 9: 4835-4845.

［40］MCPHERSON S, WILKINSON N, TINIAKOS D, et al. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis［J］. PLoS One, 2017, 12(4): e0175717.

引证本文

王欣, 胡义扬, 刘平, 等. 高血压与非酒精性脂肪性肝病的关系[J]. 临床肝胆病杂志, 2020, 36(11): 2584-2588.